MedPath

Effect of metformin and L-carnitine in treatment of fatty liver

Phase 3
Recruiting
Conditions
non alcoholic fatty liver disease.
Fatty (change of) liver, not elsewhere classified
K76.0
Registration Number
IRCT20150706023083N3
Lead Sponsor
Tabriz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
68
Inclusion Criteria

Age range 18_65 years old
Patients based on ultrasound evidence and testing of non-alcoholic fatty liver

Exclusion Criteria

People under the age of 18
Pregnant and lactating women
People with kidney failure 30>GFR
People with heart failure HF Class 3 and 4
People with liver cirrhosis

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum Spartate Aminotransferase Level. Timepoint: On arrival and after intervention. Method of measurement: Laboratory methods with Kits.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath